Pörssitiedote

Pharma publishes its Annual Report for 2025

Uppsala, Sweden, April 9, 2026. Today, the pharmaceutical company Dicot Pharma AB publishes its Annual Report for 2025.

2025 was marked by significant progress for Dicot Pharma and the development of the drug candidate LIB‑01 for the treatment of erectile dysfunction. Positive results from the phase 2a study, together with a deeper understanding of LIB‑01’s mechanism of action, have laid a solid foundation for continued development and contributed to increased international attention.

The full Annual Report including the Auditor’s Report is available in English at www.dicotpharma.com/en/investor-relations/.

About Dicot Pharma AB
Dicot Pharma is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot Pharma’s business model involves evaluating industrial and financial partnerships during clinical development to bring LIB-01 to commercialization on the world market.

Dicot Pharma is listed on Nasdaq First North and has approximately 17,000 shareholders. FNCA Sweden AB is appointed Certified Adviser. For more information, please visit www.dicotpharma.com.

This is a translation from the Swedish original. In case of differences between versions, the Swedish version prevails.